Form 4: Regeneron Director Acquires Stock, Options

Regeneron Pharmaceuticals director N. Anthony Coles acquired 155 restricted stock units and 1,962 non-qualified stock options.

Summary

• Director N. Anthony Coles acquired 155 shares of Regeneron Pharmaceuticals, Inc. common stock in the form of time-based vesting restricted stock units on January 2, 2026.
• Coles also acquired 1,962 non-qualified stock options to buy common stock at an exercise price of $772.76 per share on January 2, 2026.
• The restricted stock units represent a contingent right to receive one share of common stock each, with a transaction price of $0.0, indicating a grant.
• The non-qualified stock options were granted at a price of $0.0 and have an expiration date of January 2, 2036.
• A portion of these stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder becoming exercisable on the first anniversary of the grant date.
• Following these transactions, Coles beneficially owns 1,714 shares of common stock and 1,962 non-qualified stock options directly.

Sentiment

Score: 7

Explanation: The filing reflects routine equity compensation for a director, which is a positive for aligning interests but does not indicate significant new operational or financial news. The grants incentivize long-term commitment.

Positives

• Director N. Anthony Coles received additional equity compensation, which aligns his interests with those of shareholders.
• The acquisition of restricted stock units and stock options indicates continued commitment and incentivization for the director's long-term service to the company.

Future Outlook

The filing details future vesting schedules for the acquired stock options, with a portion becoming exercisable after the Issuer's first annual meeting following the grant date and the remainder on the first anniversary of the grant date, indicating a long-term incentive structure.

Industry Context

This filing represents a routine equity compensation grant to a director, common practice in the biotechnology and pharmaceutical industries to align executive and director interests with long-term company performance and shareholder value. Such grants are a standard component of compensation packages for directors in publicly traded companies like Regeneron Pharmaceuticals.

Comparison to Industry Standards

• The grant of restricted stock units and non-qualified stock options to a director is a standard compensation practice within the pharmaceutical and biotechnology sectors, comparable to incentive structures seen at companies like Amgen, Gilead Sciences, or Pfizer.
• The specific number of units and options, and the exercise price, are typically determined by the company's compensation committee based on market benchmarks for director compensation, company performance, and individual contributions.
• Without specific compensation committee reports or peer group data, a direct quantitative comparison is not feasible from this filing alone, but the type of compensation is consistent with industry norms.

Related Party Transactions

• The transactions involve a director of Regeneron Pharmaceuticals, Inc. receiving equity compensation, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation.
• Management: The grants are part of the overall compensation structure for the board, incentivizing leadership.

Next Steps

• A portion of the acquired stock options will become exercisable on the date of Regeneron's first annual meeting of shareholders following January 2, 2026.
• The remainder of the stock options will become exercisable on the first anniversary of the grant date (January 2, 2027).

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director and does not contain information that would fundamentally alter the investment thesis for Regeneron Pharmaceuticals. The grants are standard practice for aligning director interests with long-term shareholder value but do not signal new operational performance or strategic shifts that would warrant a change in investment recommendation based solely on this filing.

Keywords

Regeneron Pharmaceuticals, REGN, N. Anthony Coles, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Biotechnology, Pharmaceuticals